Celltrion is strengthening its presence in the European market by expanding the sales of its biosimilars in Italy. The company is accelerating its market share growth with key products, including 'Omniclo' (ingredient name: omalizumab), which was launched last year.
On July 31, Celltrion announced that the sales of Omniclo, a treatment for chronic spontaneous urticaria and allergic asthma launched in Italy at the end of last year, are continuing to expand.
Celltrion's Italian subsidiary is currently selling Omniclo in 15 regions. Among these, seven regional governments have signed contracts exclusively with Celltrion as a supplier of omalizumab.
The company explained that in some areas, the sales volume of Omniclo from January to May this year surpassed the total prescriptions of omalizumab during the same period last year.
Celltrion also reported that its autoimmune disease treatments, 'Stekima' (ingredient name: ustekinumab) and 'Aptozma' (ingredient name: tocilizumab), launched in Italy last year, are being sold in several regions.
Additionally, the autoimmune treatment 'Uplima' (ingredient name: adalimumab) and the anticancer drug 'Vegzelma' (ingredient name: bevacizumab) recorded market shares of 46% and 66%, respectively, in the Italian market during the first quarter of this year, continuing their growth trend.
Celltrion plans to promote its market share expansion in Europe by focusing on Omniclo, Aptozma, and the Remsima product line.
Yoo Won-sik, head of Celltrion's Italian subsidiary, stated, "New products, including Omniclo, have achieved significant bidding results in key regions. We will strengthen the presence of new biosimilars through participation in bids and expansion of supply areas in the second half of the year."
Meanwhile, Celltrion reported a consolidated revenue of 1.3937 trillion won and an operating profit of 451.8 billion won for the second quarter, driven by the sales expansion of high-margin new products.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.